Hosted on MSN29d
New drug shows promise in reducing aortic valve surgeriesMore information: Bin Zhang et al, Reactivation of Oxidized Soluble Guanylate Cyclase as a Novel Treatment Strategy to Slow Progression of Calcific Aortic Valve Stenosis: Preclinical and ...
A novel therapeutic showed significant promise in slowing aortic valve calcification, potentially extending time until or eliminating need for transcatheter or surgical intervention for stenosis, ...
which will soon begin in collaboration with an industry partner (1 Trusted Source Reactivation of Oxidized Soluble Guanylate Cyclase as a Novel Treatment Strategy to Slow Progression of ...
The nitric oxide-independent soluble guanylate cyclase activator ataciguat continued to show promise for slowing the progression of fibrocalcific aortic valve stenosis in phase I and II studies.
NO then reacts with guanylate cyclase in vascular smooth muscle to produce cGMP that reduces intracellular calcium concentrations resulting in relaxation of vascular smooth muscle and consequent ...
Stephen, R., Palczewski, K., Sousa, M.C. (2008) Ca2+-dependent regulation of phototransduction. Photochem. And Photobiol. 84. 903-910 Stephen, R. (2008) Structural ...
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The nitric oxide-independent soluble guanylate cyclase activator ataciguat continued to show promise for slowing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback